Vanguard Capital Management
MEDS

Vanguard Capital Management’s DataMeds AI MEDS Stock Holding History

Vanguard Capital Management’s Portfolio MEDS Stock Details MEDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.4K Sell
11,085
-1,000
-8% -$4.92K ﹤0.01% 3967
2026
Q1 		$58K Buy
+12,085
New +$166K ﹤0.01% 3905

Other funds holding MEDS

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Vanguard Capital Management's MEDS Position: Q2 2026 in Review

Vanguard Capital Management reduced its DataMeds AI (MEDS) stake by 8.3% in Q2 2026, selling an estimated $4.92K and leaving 11,085 shares worth $34.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3967.

Vanguard Capital Management first reported a position in MEDS in Q1 2026 and has held it in 2 quarters since. The position peaked at $58K in Q1 2026. 9 funds tracked by Wall St. Rank hold MEDS as of Q2 2026.

  • Vanguard Capital Management held 11,085 shares of DataMeds AI worth $34.4K as of Q2 2026.
  • Vanguard Capital Management sold 1,000 DataMeds AI shares in Q2 2026, an estimated $4.92K.
  • DataMeds AI made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3967 holding.
  • Vanguard Capital Management first reported a position in DataMeds AI in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's DataMeds AI position peaked at $58K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held DataMeds AI as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.